Search
Avita Medical's ReCell regenerative medicine technology.

Avita seeks US market pre-approval

Health technology company Avita Medical has submitted a pre-market approval application to the US Food and Drug Administration for its ReCell regenerative medicine technology.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/03/19

1 year TSR5 year TSR
5thAvita Medical400%22%
16thOnterran231%-3%
117thEnergy Developments33%-7%
253rdAspen Group2%1%
765thKyckr-70%
729 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

10/01/19
$0 Other
10/01/19
$0 Other
10/01/19
$15k Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

63rd-Energy Developments$27.2m
64th-Aspen Group$22.1m
65th-Avita Medical$11.3m
66th-Kyckr$2.2m
67th-Onterran$1.6m
79 listed non wa companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer